Home > Riviste > International Angiology > Fascicoli precedenti > International Angiology 2000 March;19(1) > International Angiology 2000 March;19(1):35-8

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

INTERNATIONAL ANGIOLOGY

Rivista di Angiologia


Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,37


eTOC

 

ORIGINAL ARTICLES  


International Angiology 2000 March;19(1):35-8

Copyright © 2001 EDIZIONI MINERVA MEDICA

lingua: Inglese

Effects of bunazosin hydrochloride sustained-release formulation on cerebral circulation

Mochizuki Y., Oishi M., Takasu T.

From the Department of Neurology, Nihon University School of Medicine, Tokyo, Japan


PDF  


Background. We inves­ti­gat­ed the cere­bral blood flow in mild to mod­er­ate­ly hyper­ten­sive ­patients with chron­ic cere­bral infarc­tion ­before and after the admin­is­tra­tion of bunaz­o­sin hydro­chlo­ride sus­tained-­release for­mu­la­tion, a selec­tive sym­pa­thet­ic α1 recep­tor block­er.
Methods. Eleven mild to mod­er­ate­ly hyper­ten­sive ­patients (mean age 65.6 years) with chron­ic cere­bral infarc­tion were stud­ied. Interventions: The ­patients were on enal­a­pril ­maleate, an angio­ten­sin con­vert­ing ­enzyme inhib­i­tor, for one week and then enal­a­pril ­maleate was ­switched to bunaz­o­sin hydro­chlo­ride sus­tained-­release for­mu­la­tion. Measures: The cere­bral blood flow study was per­formed ­before and 8 weeks after start­ing the admin­is­tra­tion of bunaz­o­sin hydro­chlo­ride sus­tained-­release for­mu­la­tion. Cerebral blood flow was meas­ured using the ­stable xenon CT meth­od. The pic­ture anal­y­sis was per­formed using AZ-7000. The region­al cere­bral blood flow was meas­ured by plac­ing the ­region of inter­est on the CT imag­es. The region­al cere­bral blood flows were meas­ured ­before and 20 min­utes after intra­ve­nous injec­tion of 17 mg/kg acet­a­zol­a­mide.
Results. The blood flows in the parie­tal cor­tex and cau­date nucle­us 8 weeks after start­ing the admin­is­tra­tion of bunaz­o­sin hydro­chlo­ride sus­tained-­release for­mu­la­tion were sig­nif­i­cant­ly great­er than those ­before. The cereb­ro­vas­cu­lar acet­a­zol­a­mide reac­tiv­ity in the occip­i­tal cor­tex and cau­date nucle­us was sig­nif­i­cant­ly lower after switch­ing to bunaz­o­sin hydro­chlo­ride sus­tained-­release for­mu­la­tion than ­before.
Conclusions. Considering the ­reports that angio­ten­sin con­vert­ing ­enzyme inhib­i­tors show lit­tle influ­ence on cere­bral blood flow, the ­present study sug­gests that bunaz­o­sin hydro­chlo­ride sus­tained-­release for­mu­la­tion may show a good influ­ence on cere­bral blood flow in mild to mod­er­ate­ly hyper­ten­sive ­patients with chron­ic cere­bral infarc­tion.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail